Minimizing Complications of Inguinal Lymph Node Dissection
By: Reza Nabavizadeh, MD, Mayo Clinic, Rochester, Minnesota; Viraj Master, MD, PhD, Emory University School of Medicine, Atlanta, Georgia, Winship Cancer Institute of Emory University, Atlanta, Georgia
Patterns of Care in the Management of Urethral Stricture Disease
By: Eric Y. Cho, MD, UC San Diego Health, California; Jill C. Buckley, MD, FACS, UC San Diego Health, California
Endoscopic Management of Upper Tract Urothelial Carcinoma: New Lasers and Techniques
By: Raymond Khargi, MD, Icahn School of Medicine at Mount Sinai, New York, New York; Alan J. Yaghoubian, MD, Icahn School of Medicine at Mount Sinai, New York, New York; Anna Ricapito, MD, Icahn School of Medicine at Mount Sinai, New York, New York, University of Foggia, Italy; Mantu Gupta, MD, Icahn School of Medicine at Mount Sinai, New York, New York
Machine Learning in Female Pelvic Medicine and Reconstructive Surgery, Urology, and Beyond
By: Glenn T. Werneburg, MD, PhD
AUANews March & AUANews March Extra 2023
The latest issue of AUANews is online! Read every article, search by topic and other keywords, all from the comfort of your digital device!
View by Topics
Top 4 Articles
Multimodal Therapy for Patients With High-grade, High-risk Prostate Cancer With Long-term Follow-up
By: Jason Robert Gee, MD; John André Libertino, MD
Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: Reviewing the Latest Evidence
By: Marcio A. Averbeck, MD, MSc, PhD, TiSBU
JU INSIGHT: Transurethral Resection of Bladder Tumor vs Chemoablation for Nonmuscle-invasive Bladder Cancer
By: Taylor Parisse, BA*; Katy Reines, MD*; Ramsankar Basak, PhD; Dana Mueller, MS; Randall Teal, MA; Maihan B. Vu, DrPH, MPH; Jessica Carda-Auten, MPH; Kathryn Stein; Kara Giannone, MPH; Robert Lipman; Angela B. Smith, MD, MS
Citrate Alkali Content of Common Over-the-Counter and Medical Food Supplements
By: Brett A. Johnson, MD
A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer
Current first-line treatment for advanced urothelial carcinoma (aUC) is platinum-based (preferably cisplatin) combination chemotherapy. In the second-line setting, pembrolizumab immunotherapy is standard. Taxane chemotherapy had shown single-agent activity. We sought to evaluate the combination of nab-paclitaxel (NAB) and pembrolizumab in patients with cisplatin-ineligible or platinum-refractory aUC.
Out of Office
Have you ever wondered what your favorite urologists do in their spare time? From piloting planes to living on a fully operational farm, learn more about their stories here.
Use "Celebrating Diversity with the AUA" focus issues as resources for years to come.
These Highlight Issues feature state-of-the-art research in the advancement of treatment of prostate cancer.
These Highlight Issues feature state-of-the-art reserch in the advancement of treatment of kidney stones.